Johnson & Johnson has completed its $6.5 billion acquisition of Momenta Pharmaceuticals Inc., it announced this week.
The all-cash deal, first announced in August, sees New Brunswick-based J&J add a company that develops novel therapies for immune-mediated diseases.
“We’re delighted to welcome Momenta’s talented team to the Janssen Pharmaceutical Cos. of Johnson & Johnson, and to begin our work together to further advance patient care in autoantibody-driven diseases,” Jennifer Taubert, executive vice president and worldwide chairman, pharmaceuticals, said in a prepared statement. “We anticipate multiple launches, many of which would be first-in-class indications in rare diseases and areas of significant unmet need.”
The deal was driven by the opportunity to add nipocalimab, an anti-FcRn antibody that was designed to target a number of autoantibody-driven conditions, such as Myasthenia Gravis and other serious diseases, J&J said in August.
